Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) was upgraded by investment analysts at Citigroup Inc. from a “sell” rating to a “neutral” rating in a research report issued to clients and investors on Wednesday. The firm presently has a $7.00 price objective on the biopharmaceutical company’s stock. Citigroup Inc.’s target price indicates a potential upside of 12.36% from the company’s current price.

Other equities research analysts have also recently issued research reports about the stock. Vetr cut shares of Keryx Biopharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $5.93 target price for the company. in a research report on Monday, October 3rd. Maxim Group raised Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a research note on Wednesday, November 9th. FBR & Co reaffirmed a “hold” rating on shares of Keryx Biopharmaceuticals in a research note on Saturday, November 19th. Finally, Zacks Investment Research raised Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, November 1st. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $8.72.

Analyst Recommendations for Keryx Biopharmaceuticals (NASDAQ:KERX)

Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) traded up 1.685% on Wednesday, hitting $6.335. 796,161 shares of the stock traded hands. The stock’s market cap is $671.26 million. Keryx Biopharmaceuticals has a 1-year low of $2.80 and a 1-year high of $7.80. The stock has a 50 day moving average of $5.92 and a 200-day moving average of $5.49.

Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.20) by $0.19. The business earned $6.30 million during the quarter, compared to the consensus estimate of $5.53 million. Keryx Biopharmaceuticals had a negative net margin of 584.76% and a negative return on equity of 270.26%. The company’s revenue was up 50.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.29) EPS. On average, equities research analysts expect that Keryx Biopharmaceuticals will post ($1.42) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This report was first posted by Watch List News and is the propert of of Watch List News. If you are reading this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright law. The original version of this report can be read at http://www.watchlistnews.com/citigroup-inc-upgrades-keryx-biopharmaceuticals-inc-kerx-to-neutral/1060209.html.

Hedge funds and other institutional investors have recently modified their holdings of the company. FMR LLC increased its position in shares of Keryx Biopharmaceuticals by 45.1% in the second quarter. FMR LLC now owns 3,168,664 shares of the biopharmaceutical company’s stock valued at $20,977,000 after buying an additional 984,472 shares during the last quarter. BlackRock Institutional Trust Company N.A. increased its position in Keryx Biopharmaceuticals by 7.3% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 2,588,613 shares of the biopharmaceutical company’s stock valued at $13,746,000 after buying an additional 175,601 shares in the last quarter. BlackRock Fund Advisors increased its position in Keryx Biopharmaceuticals by 7.3% in the third quarter. BlackRock Fund Advisors now owns 2,021,682 shares of the biopharmaceutical company’s stock valued at $10,735,000 after buying an additional 136,834 shares in the last quarter. Ameriprise Financial Inc. increased its position in Keryx Biopharmaceuticals by 22.6% in the third quarter. Ameriprise Financial Inc. now owns 1,917,643 shares of the biopharmaceutical company’s stock valued at $10,183,000 after buying an additional 353,444 shares in the last quarter. Finally, Rice Hall James & Associates LLC increased its position in Keryx Biopharmaceuticals by 45.3% in the third quarter. Rice Hall James & Associates LLC now owns 1,325,917 shares of the biopharmaceutical company’s stock valued at $7,041,000 after buying an additional 413,087 shares in the last quarter. 61.57% of the stock is owned by hedge funds and other institutional investors.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.

5 Day Chart for NASDAQ:KERX

Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.